Patent: 9,060,978
✉ Email this page to a colleague
Summary for Patent: 9,060,978
Title: | Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist |
Abstract: | Effective methods of treating a spinal disorder or osteoarthritis associated with a proinflammatory agent in a patient in need of such treatment, the method comprising administering an effective amount of DN-TNF (e.g., XPro.RTM.-1595) to a target tissue site at or near the spine or osteoarthritic joint to reduce pain and/or inflammation. |
Inventor(s): | Binette; Francois (San Francisco, CA) |
Assignee: | Warsaw Orthopedic, Inc. (Warsaw, IN) |
Application Number: | 13/280,073 |
Patent Claims: | see list of patent claims |
Details for Patent 9,060,978
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2039-02-26 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2039-02-26 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2039-02-26 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2039-02-26 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |